Mestranol
Enovid, Norethin 1/50m, Norinyl, Ortho-novum, Ovulen (mestranol) is a small molecule pharmaceutical. Mestranol was first approved as Ovulen on 1982-01-01.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Ethynodiol diacetate
+
Mestranol
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| OVULEN | G.D. Searle | N-016029 DISCN | 1982-01-01 | 1 products |
| OVULEN-21 | G.D. Searle | N-016029 DISCN | 1982-01-01 | 1 products |
| OVULEN-28 | G.D. Searle | N-016705 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Mestranol
+
Norethindrone
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| NORINYL 1+50 21-DAY | Allergan | N-013625 DISCN | 1982-01-01 | 1 products |
| NORINYL | Allergan | N-013625 DISCN | 1982-01-01 | 1 products |
| NORINYL 1+50 28-DAY | Allergan | N-016659 DISCN | 1982-01-01 | 1 products, RLD |
| NORINYL 1+80 21-DAY | G.D. Searle | N-016724 DISCN | 1982-01-01 | 1 products |
| NORINYL 1+80 28-DAY | G.D. Searle | N-016725 DISCN | 1982-01-01 | 1 products |
| ORTHO-NOVUM 1/50 28 | Johnson & Johnson | N-016709 DISCN | 1982-01-01 | 1 products |
| ORTHO-NOVUM 10-21 | Johnson & Johnson | N-012728 DISCN | 1982-01-01 | 1 products |
| ORTHO-NOVUM 1/50 21 | Johnson & Johnson | N-012728 DISCN | 1982-01-01 | 1 products |
| ORTHO-NOVUM 2-21 | Johnson & Johnson | N-012728 DISCN | 1982-01-01 | 1 products |
| ORTHO-NOVUM 1/80 21 | Johnson & Johnson | N-016715 DISCN | 1982-01-01 | 1 products |
| ORTHO-NOVUM 1/80 28 | Johnson & Johnson | N-016715 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Mestranol
+
Norethynodrel
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ENOVID | G.D. Searle | N-010976 DISCN | 1982-01-01 | 2 products |
| ENOVID-E | G.D. Searle | N-010976 DISCN | 1982-01-01 | 1 products |
| ENOVID-E 21 | G.D. Searle | N-010976 DISCN | 1982-01-01 | 1 products |
| ENOVID | G.D. Searle | N-010976 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
50 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Endometriosis | D004715 | EFO_0001065 | N80 | — | — | — | 1 | 1 | 2 |
| Pelvic pain | D017699 | — | — | — | — | — | 1 | 1 | 2 |
| Dysmenorrhea | D004412 | HP_0100607 | N94.6 | — | — | 1 | 1 | — | 2 |
| Primary ovarian insufficiency | D016649 | EFO_0004266 | E28.3 | — | — | — | 1 | — | 1 |
| Migraine disorders | D008881 | EFO_0003821 | G43 | — | — | — | 1 | — | 1 |
| Chronic pain | D059350 | HP_0012532 | — | — | — | — | 1 | — | 1 |
| Interstitial cystitis | D018856 | EFO_1000869 | N30.1 | — | — | — | 1 | — | 1 |
| Visceral pain | D059265 | — | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Healthy volunteers/patients | — | — | — | 9 | — | 2 | — | 1 | 12 |
| Contraception | D003267 | — | — | — | — | 4 | — | — | 4 |
| Rheumatoid arthritis | D001172 | EFO_0000685 | M06.9 | 1 | — | 1 | — | — | 2 |
| Systemic lupus erythematosus | D008180 | HP_0002725 | M32 | 1 | — | 1 | — | — | 2 |
| Ovulation | D010060 | — | — | — | — | 1 | — | — | 1 |
| Covid-19 | D000086382 | — | U07.1 | — | — | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Hiv infections | D015658 | EFO_0000764 | B20 | 1 | 1 | — | — | 1 | 3 |
| Pregnancy | D011247 | EFO_0002950 | Z33.1 | — | 1 | — | — | — | 1 |
| Polycystic ovary syndrome | D011085 | EFO_0000660 | E28.2 | — | 1 | — | — | — | 1 |
| Hyperandrogenism | D017588 | — | — | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 2 | — | — | — | — | 2 |
| Pharmacokinetics | D010599 | — | — | 1 | — | — | — | — | 1 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | — | 1 |
| Psoriatic arthritis | D015535 | EFO_0003778 | L40.5 | 1 | — | — | — | — | 1 |
| Psoriasis | D011565 | EFO_0000676 | L40 | 1 | — | — | — | — | 1 |
| Inflammatory bowel diseases | D015212 | EFO_0003767 | — | 1 | — | — | — | — | 1 |
| Arthritis | D001168 | HP_0001369 | M05-M14 | 1 | — | — | — | — | 1 |
| Infections | D007239 | EFO_0000544 | — | 1 | — | — | — | — | 1 |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | 1 | — | — | — | — | 1 |
| Hepatitis c | D006526 | — | B19.2 | 1 | — | — | — | — | 1 |
Show 2 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Venous thrombosis | D020246 | HP_0004936 | I82.40 | — | — | — | — | 1 | 1 |
| Pulmonary embolism | D011655 | HP_0002204 | I26 | — | — | — | — | 1 | 1 |
| Intracranial sinus thrombosis | D012851 | — | — | — | — | — | — | 1 | 1 |
| Myocardial ischemia | D017202 | EFO_1001375 | I20-I25 | — | — | — | — | 1 | 1 |
| Headache | D006261 | HP_0002315 | R51 | — | — | — | — | 1 | 1 |
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Mestranol |
| INN | mestranol |
| Description | Mestranol is a terminal acetylenic compound that is (17alpha)-17-ethynylestra-1(10),2,4-triene substituted by a methoxy group at position 3 and a hydroxy group at position 17. It has a role as a prodrug and a xenoestrogen. It is a 17beta-hydroxy steroid, a terminal acetylenic compound and an aromatic ether. It is functionally related to a 17beta-estradiol. |
| Classification | Small molecule |
| Drug class | estrogens |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | C#C[C@]1(O)CC[C@H]2[C@@H]3CCc4cc(OC)ccc4[C@H]3CC[C@@]21C |
Identifiers
| PDB | — |
| CAS-ID | 72-33-3 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1201151 |
| ChEBI ID | 6784 |
| PubChem CID | 6291 |
| DrugBank | DB01357 |
| UNII ID | B2V233XGE7 (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
₣
No data
Estimated US medical usage
Mestranol
+
Norethindrone
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,218 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
342 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use